AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3056431
Drug: Gemfibrozil 600
RxNorm normalized name: gemfibrozil 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil 600 mg bid
Trial: 3056431
Drug: Clofibrate 1000
RxNorm normalized name: clofibrate 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofibrate 1000 mg bid
Trial: 19333169
Drug: Clonidine-bupivacaine nerve-stimulator
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine-bupivacaine nerve-stimulator guided injection (9 mL bupivacaine 0.5% and 1 mL clonidine 150 mcg/mL)
Trial: 19333169
Drug: Bupivacaine guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine guided injection (9 mL bupivacaine 0.5% and 1 mL saline)
Trial: 31780418
Drug: Clopidogrel as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel as mono antiplatelet therapy (MAPT) after COBRA PzF NCS implantation
Trial: 28494920
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept (2 mg/0.05 mL at baseline, 4 weeks, and 8 weeks; reviewed every 4 weeks thereafter with injections as needed)
Trial: 25986590
Drug: Lithium plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium plus Treatment As Usual (TAU)
Trial: 25986590
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus Treatment As Usual (TAU)
Trial: 23870047
Drug: Internet administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Internet administration of the Edinburgh Depression Scale
Trial: 23870047
Drug: Telephone administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telephone administration of the Edinburgh Depression Scale
Trial: 23870047
Drug: Pen-and-paper administration
RxNorm normalized name: caper berry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pen-and-paper administration of the Edinburgh Depression Scale
Trial: 21341893
Drug: Culturally adapted
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally adapted one-session treatment (OST-CA)
Trial: 21341893
Drug: Standard one-session
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard one-session treatment (OST-S)
Trial: 17823446
Drug: Dairy intervention
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dairy intervention group (n = 39) receiving daily approximately 1200 mg Ca and 7.5 microg vitamin D3 via fortified dairy products and biweekly nutrition education sessions
Trial: 17823446
Drug: Calcium‐supplemented group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium‐supplemented group (n = 26) receiving a total of 1200 mg Ca/d
Trial: 15114779
Drug: Low-molecular heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular heparin dalteparin (n = 31)
Trial: 15114779
Drug: Non-fractionated heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-fractionated heparin (n = 17)
Trial: 9556902
Drug: Patch containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch containing 4.0 mg of E2 in a reservoir system
Trial: 9556902
Drug: Patch containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch containing 1.8 mg of E2 in a specially designed matrix system
Trial: 9556902
Drug: Matrix system
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matrix system patches
Trial: 31722135
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of α-lipoic acid
Trial: 25904367
Drug: Weekly rifapentine
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly rifapentine plus isoniazid (3HP)
Trial: 25904367
Drug: Daily isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily isoniazid (9H)
Trial: 19552744
Drug: Rabeprazole (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole (7 days) with antibiotics (clarithromycin and amoxicillin) given on days 1-4, 4-7, or 1-7
Trial: 15497665
Drug: Clarithromycin 250
RxNorm normalized name: clarithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 250 mg test tablets
Trial: 15497665
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg test tablets
Trial: 15497665
Drug: Reference tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference tablets of the same strength (250 mg and 500 mg)
Trial: 11456368
Drug: 89Sr‐chloride (527
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 89Sr‐chloride (527 treatments)
Trial: 11456368
Drug: 186Re‐HEDP (83
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 186Re‐HEDP (83 treatments)
Trial: 11456368
Drug: Retreatments (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retreatments (up to five injections, 100 total)
Trial: 10923463
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg/kg administered at 60 seconds
Trial: 10923463
Drug: Rocuronium maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium maintenance (either intravenous infusion or bolus injection)
Trial: 10923463
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg/kg administered at 90 seconds
Trial: 2499730
Drug: ubinon (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ubinon (90 and 135 mg/day)
Trial: 31829404
Drug: Primary tumour
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary tumour resection plus chemotherapy
Trial: 24151394
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy alone (O‐G+t group)
Trial: 24151394
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy and mouthrinse treatment (O+G+tm group)
Trial: 24151394
Drug: Triple therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy, mouthrinse, and periodontal treatment (O+G+tmp group)
Trial: 24151394
Drug: O‐G+t group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O‐G+t group
Trial: 24151394
Drug: O+G+t group
RxNorm normalized name: Padimate O
DrugBank: Padimate O (DB11570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: O+G+t group
Trial: 24151394
Drug: O+G+tm group
RxNorm normalized name: Padimate O
DrugBank: Padimate O (DB11570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: O+G+tm group
Trial: 24151394
Drug: O+G+tmp group
RxNorm normalized name: Padimate O
DrugBank: Padimate O (DB11570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: O+G+tmp group
Trial: 21334096
Drug: Griseofulvin (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Griseofulvin (mean duration of treatment 8 weeks, range 6‐12 weeks)
Trial: 21334096
Drug: Terbinafine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine (mean duration of treatment 4 weeks, range 2‐6 weeks)
Trial: 17083726
Drug: Moderate-to-severe asthmatics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-to-severe asthmatics on inhaled steroid treatment
Trial: 15617307
Drug: Brimonidine 0.2%
RxNorm normalized name: BRIMONIDINE 0.2%/TIMOLOL 0.5% OPH SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine 0.2% twice daily (BID) for 4 weeks
Trial: 15617307
Drug: Brimonidine 0.2%
RxNorm normalized name: BRIMONIDINE 0.2%/TIMOLOL 0.5% OPH SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine 0.2% three times daily (TID) for 4 weeks
Trial: 7871001
Drug: tropisetron 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tropisetron 0.5 mg daily
Trial: 7871001
Drug: tropisetron 5
RxNorm normalized name: tropisetron 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tropisetron 5 mg daily
Trial: 7871001
Drug: tropisetron 25
RxNorm normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tropisetron 25 mg daily
Trial: 7871001
Drug: tropisetron (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tropisetron (all doses)
Trial: 3531149
Drug: Other slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other slow-release theophylline formulation
Trial: 30613992
Drug: PICC removal
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PICC removal and PN discontinuation at an enteral feed volume of 100 mL/kg/day
Trial: 30613992
Drug: PICC removal
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PICC removal and PN discontinuation at an enteral feed volume of 140 mL/kg/day
Trial: 22001758
Drug: Mechanical ventilation
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical ventilation with tidal volume (V(T)) of 12 mL/kg ideal body weight with zero positive end‐expiratory pressure (PEEP)
Trial: 22001758
Drug: Mechanical ventilation
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical ventilation with tidal volume (V(T)) of 6 mL/kg ideal body weight with PEEP of 8 cm H(2)O
Trial: 20810669
Drug: Metformin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (250 mg/d)
Trial: 17953380
Drug: Preoperative preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative preparation method of sequential thyroid defunctionalization (subgroup A)
Trial: 17953380
Drug: Preoperative preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative preparation method of sequential thyroid defunctionalization (subgroup B)
Trial: 17953380
Drug: Preoperative preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative preparation method of sequential thyroid defunctionalization (subgroup C)
Trial: 17953380
Drug: Preoperative preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative preparation method of sequential thyroid defunctionalization (subgroup D)
Trial: 17953380
Drug: Preoperative preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative preparation method of sequential thyroid defunctionalization (test group)
Trial: 17953380
Drug: Antithyroid drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithyroid drugs and iodine preparation (control group)
Trial: 10219883
Drug: rec-GH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rec-GH therapy (C=0.6 IU/kg/week for C, CO=0.5 IU/kg/week, A=0.25 IU/kg/week) for 12 months (C and A) and 6 months (CO)
Trial: 10219883
Drug: rec-GH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rec-GH therapy
Trial: 1619179
Drug: Thiamin intake
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiamin intake greater than or equal to 1.0 mg/day
Trial: 1619179
Drug: Vitamin B6
RxNorm normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B6 intake at the current recommended dietary allowance (1.6 mg)
Trial: 6322681
Drug: Ceftriaxone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (100 mg/kg per day in two doses for a minimum of 10 days)
Trial: 6322681
Drug: Traditional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional therapy (ampicillin and chloramphenicol or gentamicin, pending sensitivity)
Trial: 25072436
Drug: DJBL treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DJBL treatment with dietary intervention
Trial: 17507105
Drug: sarpogrelate (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sarpogrelate (300 mg/day) plus aspirin (100 mg/day)
Trial: 17507105
Drug: ticlopidine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ticlopidine (200 mg/day) plus aspirin (100 mg/day)
Trial: 16323175
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no voice therapy)
Trial: 10664525
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor MPV 2213ad, single dose of 100mg
Trial: 10664525
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor MPV 2213ad
Trial: 7640644
Drug: Caffeine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (6 mg.kg‐1) administered 2‐1/2 hrs prior to swim trial
Trial: 7640644
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 2‐1/2 hrs prior to swim trial
Trial: 2665027
Drug: Clenbuterol (0.0012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clenbuterol (0.0012 mg/kg/day) solution bid for one week
Trial: 2665027
Drug: Terbutaline (0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (0.075 mg/kg/day) solution tid
Trial: 363071
Drug: Naprosyn (naproxen)
RxNorm normalized name: naproxen Oral Suspension [Naprosyn]
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naprosyn (naproxen) 750 mg daily
Trial: 29229103
Drug: Budesonide/formoterol pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol pMDI 320/9 μg BID
Trial: 29229103
Drug: Formoterol DPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol DPI 9 μg BID
Trial: 18433672
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of 0.2% ropivacaine 10 mL/h (group R, n = 22)
Trial: 18433672
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of 0.9% NaCl 10 mL/h (group S, n = 22)
Trial: 14556808
Drug: Peritoneal fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritoneal fluid IL-18 levels in women with superficial peritoneal implants
Trial: 14556808
Drug: Peritoneal fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritoneal fluid IL-18 levels in women with deep peritoneal implants
Trial: 11073017
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (2 g elemental calcium daily)
Trial: 11073017
Drug: Fibre supplementation
RxNorm normalized name: Fiore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibre supplementation (3.5 g ispaghula husk)
Trial: 8398526
Drug: lumbar extradural
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lumbar extradural analgesia using 0.5% bupivacaine 1 mg kg‐1 plus morphine 50 micrograms kg‐1
Trial: 8398526
Drug: morphine 100
RxNorm normalized name: MORPHINE 100MG/NALTREXONE 4MG SA CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine 100 micrograms kg‐1 i.m.
Trial: 8398526
Drug: subpubic block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subpubic block using 0.5% bupivacaine 0.5 mg kg‐1 for each side
Trial: 24991030
Drug: Noninvasive repetitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noninvasive repetitive transorbital alternating current stimulation (rtACS; 10 days, 40 minutes daily; n = 7)
Trial: 22910840
Drug: Second line
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second line therapy (platinum combination, n = 313, 24.5%)
Trial: 22910840
Drug: Third line
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third line therapy (topotecan, n = 118, 23.6%)
Trial: 22910840
Drug: Fourth line
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fourth line therapy
Trial: 22910840
Drug: Fifth line
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fifth line therapy
Trial: 15976235
Drug: Carbamazepine 100
RxNorm normalized name: carbamazepine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine 100 mg
Trial: 9085622
Drug: Cimetidine 200
RxNorm normalized name: cimetidine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 200 mg IV after 500 ml of enteral nutrition
Trial: 9085622
Drug: Ranitidine 50
RxNorm normalized name: ranitidine 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 50 mg IV after 500 ml of enteral nutrition
Trial: 26864124
Drug: Liraglutide (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (not specified dosage or duration)
Trial: 26864124
Drug: Treatment intensity
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment intensity (insulin, statins, oral antihypertensive drugs)
Trial: 19827461
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (CD), 5.5 +/- 0.3 g/d of L-arginine
Trial: 19827461
Drug: Diet 2
RxNorm normalized name: gluc-msm-vit C-FA-mang-diet 29 125 mg-37.5 mg-25 mg-500 mcg-1.25 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet 2 (same as CD but including an oral supplement of 15 g/d), 20.5 +/- 0.3 g/d of L-arginine
Trial: 9492093
Drug: Free fraction
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free fraction of L-tryptophan in plasma
Trial: 9492093
Drug: L-tryptophan and
RxNorm normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-tryptophan and serotonin synthesis
Trial: 9492093
Drug: Free fraction
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free fraction of plasma L-tryptophan
Trial: 3266541
Drug: Sodium metabisulfite
RxNorm normalized name: Sodium Metabisulfite
DrugBank: Sodium metabisulfite (DB15842)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium metabisulfite solutions (0.5, 1, 10, 25, 50 mg, 100 mg, 200 mg)
Trial: 26092062
Drug: Weekly teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly teriparatide
Trial: 11025425
Drug: Neoadjuvant hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant hormonal therapy (NHT) prior to radical prostatectomy
Trial: 11025425
Drug: Neoadjuvant hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant hormonal therapy (NHT) prior to radiation therapy
Trial: 9309996
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (NO) at 40 ppm
Trial: 3770017
Drug: Propranolol and
RxNorm normalized name: propranolol and thiazides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol and diuretic
Trial: 3770017
Drug: Sotalol and
RxNorm normalized name: sotalol and thiazides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol and diuretic
Trial: 26914585
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccine (H1N1 strain)
Trial: 26914585
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccine (H3N2 strain)
Trial: 26914585
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccine (B strain)
Trial: 22640372
Drug: Osteo-cise intervention
RxNorm normalized name: Osteo-Poretical
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Osteo-cise intervention (multi-modal exercise program with high velocity progressive resistance training, moderate impact weight-bearing exercise, and high challenging balance exercises performed three times weekly)
Trial: 20119672
Drug: Intraoperative periarticular
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative periarticular multimodal drug injections (PMDI)
Trial: 12095018
Drug: Meperidine (rescue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (rescue medication)
Trial: 8919987
Drug: morphine 0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine 0.50 mg/ml + ketorolac 1.50 mg/ml (Group 2)
Trial: 8919987
Drug: morphine 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine 0.75 mg/ml + ketorolac 0.75 mg/ml (Group 1)
Trial: 8919987
Drug: morphine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine 0.25 mg/ml + ketorolac 1.50 mg/ml (Group 3)
Trial: 400713
Drug: Intravenous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous insulin (iv)
Trial: 400713
Drug: Intramuscular insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular insulin (im)
Trial: 400713
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin (sc)